Pesquisador Responsável por auxílio Jovem Pesquisador FAPESP, InCor 2013. Pós-doutorado pela Faculdade de Medicina da Universidade de São Paulo (USP-SP - 2013), no Laboratório de Genética e Cardiologia Molecular do Instituto do Coração do Hospital das Clínicas (InCor-HC/FMUSP). Doutor pelo Programa de Pós-Graduação da Faculdade de Ciências Farmacêuticas da USP-SP (CAPES 7 - 2011). Possui graduação em Farmácia-Bioquímica e habilitação em Análises Clínicas (ENADE-5, 2005, 2006) pela Universidade Federal de Alfenas, MG (UNIFAL-MG). Ganhador do Prêmio Jovem Geneticista 2011 pela Sociedade Brasileira de Genética. Responsável por auxílios CNPq. Atua como revisor ad hoc de diversos periódicos internacionais. Autor de capítulos de livros, coordenou publicações de livros pela Editora GEN-Roca e pela Atheneu (em processo). Orientador de Mestrado e Doutorado pelo Programa de Pós-Graduação em Ciências Médicas da FMUSP (CAPES 7). Docente de cursos de especialização Latu-Sensu. Possui experiências em Docência e em áreas de Pesquisa. Principais temas: diagnóstico molecular em doenças monogênicas, genoma, farmacogenética, metabolismo de ferro e hemocromatose hereditária. Estudos de associação genética em fenótipos bioquímicos, farmacológicos, hematológicos e cardiovasculares. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Pharmacogenetic Evaluation for Calcineurin Inhibitor Immune Prophylaxis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation, São Paulo, 2025.Introduction: In 2023, nearly 1,694 allogeneic transplants were performed in Brazil. There are several complications related to allogeneic transplantation, especially graft-versus-host disease (GVHD), which can significantly imp…
In a current review about pharmacogenomics studies in Brazil, authors showed that there are several retrospectives studies focusing on the drugs and genes. However, no prospective analyses of drug therapy outcomes or cost-effectiveness assessments of pharmacogenomics-guided therapy were found at 2018. Last years, we organized lab logistics and clinical multidisciplinary professional to pe…
Cardiovascular diseases are the main causes of death worldwide and the pharmacological treatment implementation has been one of the most responsible for reductions in morbidity and mortality recent decades. Some pharmacogenetic tests are available to healthcare professionals, and increasingly, the regulatory agencies understand the relationship pharmaco-genomics. In this project, beside i…
This project aims to study castration-resistant prostate cancer (CRPC) cells from DU-145 (isolated from brain metastasis) and PC-3 (isolated from bone metastasis) cell lines when treated with porcine heparin, specifically analyzing the expression of hepcidin, the iron-regulating hormone, and heparanase. CRPC, being resistant to androgen deprivation hormonal treatment, has a higher chance …
Although warfarin is effective, it has a narrow therapeutic interval with difficult dose adjustment, and low TTR values (time within the therapeutic range <50%) are associated with risk of adverse events and, consequently, broad public spending. Studies show that clinical and genetic factors influence warfarin dose variability. Our group developed a pharmacogenetic algorithm estimati…
Dependence on cocaine, as well as crack, is a major public health problem in Brazil and in the world. A dopaminergic neurotransmission, the brain reward system, and the cholinergic system, more information about our mechanisms of reward, self-administration, and cocaine dependence. In this context, Prof. Dr. José Carlos Fernández Galduróz (Department of Psychobiology, Paulista School of M…
Cardiovascular diseases are one of the main causes of mortality worldwide. Among them, there are the thromboembolic disorders. The warfarin, drug classified as coumarin oral anticoagulant, is widely used to treat these clinical conditions. However, according to genetic and environmental factors, coumarins have shown high variance in pharmacokinetic and pharmacodynamics, resulting in disti…
Background: Time in therapeutic range (TTR) is a measurement of quality of warfarin therapy and lower TTR values (<50%) are associated with greater risk of thromboembolic and bleeding events. Recently, we developed a pharmacogenetic-based warfarin dosing algorithm specifically calibrated for a Brazilian patient sample. The aims of this study are: to evaluate the impact of a genetic-based …
(Only some records are available in English at this moment)
| 1 / 1 | Ongoing grants |
| 2 / 2 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 10 / 8 | Completed scholarships in Brazil |
| 15 / 13 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID